Top Markets
Coin of the day
Taysha Gene Therapies, Inc. Taysha Gene Therapies, Inc.

Taysha Gene Therapies, Inc.

TSHA
Rang in aandelen #6652
Taysha Gene Therapies, Inc. is a biotech firm specializing in the creation and... Taysha Gene Therapies, Inc. is a biotech firm specializing in the creation and market introduction of gene therapies that utilize adeno-associated virus (AAV) vectors. Its core mission is to tackle inherited diseases affecting the central nervous system (CNS). The company's development pipeline features several key programs: TSHA-120 is aimed at giant axonal neuropathy; TSHA-102 is in development for Rett syndrome; TSHA-121 and TSHA-118 are both being advanced for CLN1 disease; TSHA-105 addresses SLC13A5 Deficiency; and TSHA-101 targets GM2 gangliosidosis. Furthermore, Taysha has forged a strategic alliance with The University of Texas Southwestern Medical Center to jointly advance and bring to market innovative gene therapy solutions. Founded in 2019, the company operates from its headquarters in Dallas, Texas.
Aandeelprijs
$6.02
Laatst gesynchroniseerd: 2026-08-27
Marktkapitalisatie
$1.93B
Verandering (1 dag)
0.00%
Verandering (1 jaar)
112.72%
Land
US
Handel Taysha Gene Therapies, Inc. (TSHA)

Categorie

Dividendrendementgeschiedenis voor Taysha Gene Therapies, Inc. (TSHA)
Het dividendrendement (TTM) van Taysha Gene Therapies, Inc. (aandelsymbool: TSHA) per 2026 is: 0
Gemiddeld dividendrendement over de afgelopen 5 jaar: 0.00%
Dividendrendementgeschiedenis van Taysha Gene Therapies, Inc. (TSHA) van 2026 tot 2026
Dividendrendement aan het einde van elk jaar (TTM)
Jaar Dividendrendement Wijzigen
Niet genoeg gegevens voor de verstrekte datums.
Dividendrendementen (TTM) van vergelijkbare bedrijven of concurrenten
Bedrijf Dividendrendement Land
0.00%
US
0.00%
NL
3.12%
AU
0.00%
US
0.00%
CH